 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

For the last three days, A.I.dvisor has detected that LBPH's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Longboard Pharmaceuticals (LBPH, $5.91) Aroon Indicator entered a Downtrend on September 13, 2023.

Longboard Pharmaceuticals (LBPH, $6.11) Aroon Indicator entered a Downtrend on September 12, 2023.

Longboard Pharmaceuticals (LBPH, $6.19) Aroon Indicator entered a Downtrend on September 11, 2023.

Longboard Pharmaceuticals (LBPH, $5.7) Aroon Indicator entered a Downtrend on September 08, 2023.

Longboard Pharmaceuticals (LBPH, $5.85) Aroon Indicator entered a Downtrend on September 07, 2023.

Longboard Pharmaceuticals (LBPH, $5.99) Aroon Indicator entered a Downtrend on September 06, 2023.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that...

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it...

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH Get Free Report) has been given a consensus rating of Buy by the six research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective ...

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Receives $17.40 Consensus Target Price from Brokerages

Longboard Pharmaceuticals (NASDAQ:LBPH  Get Free Report)s stock had its overweight rating reiterated by Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $16.00 target price on the stock. Cantor ...

Longboard Pharmaceuticals (NASDAQ:LBPH) Stock Rating Reaffirmed by Cantor Fitzgerald

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.

Watchers	196
52-Wk Low	$2.70
52-Wk High	$10.29

Market Cap	$142.49M
Volume (M)	40,914.00
52-Wk High	$10.29
52-Wk Low	$2.70

Current Price	$5.61
Prev Close	$5.57
Open	$5.63
Dividend Yield	0.00%
50-Day Moving Average	$6.43
Beta	0.55
Avg. Volume	96,646.70
PE Ratio	-2.20

52-Week High	$10.29
52-Week Low	$2.70
Market Capitalization	$142.49M
EPS	-$2.55
Price to Book	2.22
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-2.07

LBPH Longboard Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals